N.P. Mitkovskaya, I.A. Karpov, G.P. Arutyunov, Ye.A. Grigorenko, D.Yu. Ruzanov, T.V. Statkevich, Е.I. Tarlovskaya
COVID-19 coronavirus infection is a previously unknown acute respiratory viral infection caused by the zooanthroponous RNA-containing SARS-CoV-2 virus, first reported and described in December 2019 in the Chinese city of Wuhan. On 30 January 2020, WHO declared an international emergency and upgraded the risk assessment for COVID-19 at the global level from high to very high. The epidemic was recognized as a pandemic, in which the simultaneous infection of many people with the virus in a number of countries led to overloaded healthcare systems, an avalanche of hospitalizations and deaths.
keywords: coronavirus infection, COVID-19, SARS-CoV-2, pandemic, clinical symptoms, diagnosis, drug therapy, prevention

for references: N.P. Mitkovskaya, I.A. Karpov, G.P. Arutyunov, Ye.A. Grigorenko, D.Yu. Ruzanov, T.V. Statkevich, E.I. Tarlovskaya. COVID-19 coronavirus infection (overview of international research data). Neotlozhnaya kardiologiya i kardiovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2020, vol. 4, no. 1, pp. 784–815

1. Adhikari S.P., Meng S., Wu Y.J., Mao Y.P., Ye R.X., Wang Q.Z., Sun C., Sylvia S., Rozelle S., Raat H., Zhou H. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty, 2020, vol. 9, no. 1, pp. 29. doi: 10.1186/s40249-020-00646-x. Review.
2. Ahmed S.F., Quadeer A.A., McKay M.R. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses, 2020, vol. 12, no. 3, pp. E254. doi: 10.3390/v12030254.
3. Ahn D.G., Shin H.J., Kim M.H., Lee S., Kim H.S., Myoung J., Kim B.T., Kim S.J. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol, 2020, vol. 30, no. 3, pp. 313-324. doi: 10.4014/jmb.2003.03011.
4. Al-Abdely H.M., Midgley C.M., Alkhamis A.M., Abedi G.R., Lu X., Binder A.M., Alanazi K.H., Tamin A., Banjar W.M., Lester S., Abdalla O., et al. Middle East respiratory syndrome coronavirus infection dynamics and antibody Responses among clinically Diverse patients, Saudi Arabia. Emerg Infect Dis, 2019, vol. 25, no. 4, pp.753-766. doi:710.3201/eid2504.181595.
5. American Heart Association. Patients taking angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blocker (ARB) medications should continue therapy as prescribed [electronic resource]. Newsroom, 2020, March 17. Available at: https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician.
6. Arabi Y.M., Mandourah Y., Al-Hameed F., Sindi A.A., Almekhlafi G.A., Hussein M.A., Jose J., Pinto R., Al-Omari A., Kharaba A., Almotairi A., Al Khatib K. et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med, 2018, vol 197, no. 6, pp. 757-767. doi:10.1164/rccm.201706-1172OC.
7. Arabi Y.M., Shalhoub S., Mandourah Y., Al-Hameed F., Al-Omari A., Al Qasim E., Jose J., Alraddadi B., Almotairi A., Al Khatib K., et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis, 2019, June 25. doi:10.1093/cid/ciz544.
8. Banerjee A., Kulcsar K., Misra V., Frieman M., Mossman K. Bats and coronaviruses. Viruses, 2019, vol. 11, pii:E4. doi:10.3390/v11010041.
9. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr, 2020, vol. 14, no. 3, pp. 247-250. doi: 10.1016/j.dsx.2020.03.013.
10. Baron S.A., Devaux C., Colson P., Raoult D., Rolain J.M. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents, 2020, vol. 13, pp. 105944. doi: 10.1016/j.ijantimicag.2020.105944.
11. Bethel M.A., Patel R.A., Merrill P., Lokhnygina Y., Buse J.B., Mentz R.J., Pagidipati N.J., Chan J.C., Gustavson S.M., Iqbal N., Maggioni A.P., Öhman P., Poulter N.R., Ramachandran A., Zinman B., Hernandez A.F., Holman R.R. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol, 2018, vol. 6, no. 2, pp. 105-113. doi: 10.1016/S2213-8587(17)30412-6.
12. Burke R.M., Midgley C.M., Dratch A., Fenstersheib M., Haupt T., Holshue M., Ghinai I., Jarashow M.C., Lo J., McPherson T.D., Rudman S., Scott S., Hall A.J., Fry A.M., Rolfes M.A. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020. MMWR Morb Mortal Wkly Rep, 2020, vol. 69, no. 9, pp. 245-246. doi: 10.15585/mmwr.mm6909e1.
13. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., Li X., et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med, 2020, March 18. doi:10.1056/NEJMoa2001282.
14. Celltex Plans to Launch Program to Use Mesenchymal Stem Cells for COVID-19 related Symptoms Under an Existing Regulatory Study [electronic resource]. Business Wire, 2020, March 16. Available at: www. businesswire.com/ /home/20200316005852/en/Celltex-Plans-Launch-Program-Mesenchymal-Stem-Cells. (accessed 3.18.2020).
15. Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K., Yuan S., Yuen K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 2020, vol. 9, pp. 221-236. doi:10.1080/22221751.2020.1719902.
16. Chan K.S., Lai S.T., Chu C.M., Tsui E., Tam C.Y., Wong M.M., Tse M.W., Que T.L., Peiris J.S., Sung J., Wong V.C., Yuen K.Y. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J, 2003, vol. 9, pp. 399-411.
17. Chang L., Yan Y., Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev, 2020, Feb 21, pii: S0887-7963(20)30014-6. doi: 10.1016/j.tmrv.2020.02.003.
18. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol, 2017, vol. 39, pp. 529-539. doi: 10.10 07/s0 0281-017-0629-x.
19. Chavez S., Long B., Koyfman A., Liang S.Y. Coronavirus Disease (COVID-19): A primer for emergency physicians. Am J Emerg Med, 2020, Mar 24, S0735-6757(20)30178-9. doi: 10.1016/j.ajem.2020.03.036.
20. Chen J., Liu D., Liu L., et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci), 2020, March 6. doi:10.3785/j.issn.1008-9292.2020.03.03.
21. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., Zhang X., Zhang M., Wu S., Song J., Chen T., Han M., Li S., Luo X., Zhao J., Ning Q. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest, 2020, Mar 27. pii: 137244. doi: 10.1172/JCI137244.
22. Chen T., Dai Z., Mo P., Li X., Ma Z., Song S., Chen X., Luo M., Liang K., Gao S., Zhang Y., Deng L., Xiong Y. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci, 2020, Apr 11. pii: glaa089. doi: 10.1093/gerona/glaa089.
23. Chen X., Yu B. First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Glob Health Res Policy, 2020, vol. 2, no. 5, pp. 7. doi: 10.1186/s41256-020-00137-4.
24. Cheng P.K., Wong D.A., Tong L.K., et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet, 2004, vol. 363, no. 9422, pp. 1699-1700. doi:1610.1016/S0140-6736(1604)16255-16257.
25. Cheng Y., Luo R., Wang K. Zhang M., Wang Z., Dong L., Li J., Yao Y., Ge S., Xu G. Kidney Disease Is Associated With In-Hospital Death of Patients With COVID-19. Kidney Int, 2020, Mar. 20, pii. S0085-2538(20):30255-30256. doi: 10.1016/j.kint.2020.03.005.
26. Chow N., Fleming-Dutra K., Gierke R., Hall A., Hughes M., Pilishvili T., Ritchey M., Roguski K., Skoff T., Ussery E. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep, 2020, vol. 69, no. 13, pp. 382-386. doi: 10.15585/mmwr.mm6913e2.
27. Ciotti M., Angeletti S., Minieri M., Giovannetti M., Benvenuto D., Pascarella S., Sagnelli C., Bianchi M., Bernardini S., Ciccozzi M. COVID-19 Outbreak: An Overview. Chemotherapy, 2020, Apr 7, pp. 1-9. doi: 10.1159/000507423.
28. Colson P., Rolain J.M., Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents, 2020, vol. 55, no. 3, pp. 105923.
29. COVID-19 National Incident Room Surveillance Team. COVID-19, Australia: Epidemiology Report 3 (Reporting week ending 19:00 AEDT 15 February 2020). Commun Dis Intell (2018), 2020, Feb 20, vol. 44. doi: 10.33321/cdi.2020.44.15.
30. Dashraath P., Jing Lin Jeslyn W., Mei Xian Karen L., Li Min L., Sarah L., Biswas A., Arjandas Choolani M., Mattar C., Lin S.L. Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy. Am J Obstet Gynecol, 2020, Mar 23, S0002-9378(20)30343-4. doi: 10.1016/j.ajog.2020.03.021.
31. de Wilde A.H., Jochmans D., Posthuma C.C., Zevenhoven-Dobbe J.C., van Nieuwkoop S., Bestebroer T.M., van den Hoogen B.G., Neyts J., Snijder E.J. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother, 2014, vol. 58, no. 8, pp. 4875-4884. doi:10.1128/AAC.03011-14.
32. Deng S.Q., Peng H.J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med, 2020, vol. 9, no. 2, pp. E575. doi: 10.3390/jcm9020575.
33. Devaux C.A., Rolain J.M., Colson P., Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents, 2020, March 11. doi:10.1016/j.ijantimicag.2020.105938.
34. Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv, 2020, Feb 20. doi:10.1101/2020.02.18.20024364.
35. Ding Y., Wang H., Shen H., Li Z., Geng J., Han H. et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol, 2003, vol. 200, pp. 282-289. doi:10.1002/path.1440.
36. Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther, 2020, vol. 14, no. 1, pp. 58-60.
37. Dong L., Bouey J. Public Mental Health Crisis during COVID-19 Pandemic, China. Emerg Infect Dis, 2020, vol. 26, no. 7. doi: 10.3201/eid2607.200407.
38. Elfiky A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci, 2020, vol. 248, pp. 117477. doi: 10.1016/j.lfs.2020.117477.
39. Eurich D.T., Weir D.L., Majumdar S.R., Tsuyuki R.T., Johnson J.A., Tjosvold L., Vanderloo S.E., McAlister F.A. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail, 2013, vol. 6, no. 3, pp. 395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162.
40. Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest, 2020 Mar 28. doi: 10.1007/s40618-020-01236-2.
41. Flahault A. COVID-19 cacophony: is there any orchestra conductor? Lancet, 2020, vol. 395, no. 10229, pp. 1037. doi: 10.1016/S0140-6736(20)30491-8.
42. Fralick M., Schneeweiss S., Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med, 2017, vol. 376, no. 23, pp. 2300-2302. doi: 10.1056/NEJMc1701990.
43. Freeman M.P. COVID-19 From a Psychiatry Perspective: Meeting the Challenges.J Clin Psychiatry, 2020, vol. 8, no. 2, pp. e13.
44. Froes F. And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan. Pulmonology, 2020, vol. 26, no. 2, pp. 114-115. doi: 10.1016/j.pulmoe.2020.02.010.
45. Ganatra S., Hammond S.P., Nohria A. The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer. JACC CardioOncol, 2020, Apr 10. doi: 10.1016/j.jaccao.2020.03.001.
46. Gao J., Tian Z., Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 2020, vol. 14, no. 1, pp. 72-73. doi: 10.5582/bst.2020.01047.
47. Garcia S., Albaghdadi M.S., Meraj P.M., Schmidt C., Garberich R., Jaffer F.A., Dixon S., Rade J.J., Tannenbaum M., Chambers J., Huang P.P., Henry T.D. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic. J Am Coll Cardiol, 2020, Apr 9, pii: S0735-1097(20)34913-5. doi: 10.1016/j.jacc.2020.04.011.
48. Gaunt E.R., Hardie A., Claas E.C., et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol, 2010, vol. 48, no. 8, pp. 2940-2947. doi:2910.1128/JCM.00636-00610.
49. Gautret P., Lagier J.C., Parola P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020, March 20. doi:10.1016/j.ijantimicag.2020.105949.
50. Goh G.K., Dunker A.K., Foster J.A., Uversky V.N. Rigidity of the Outer Shell Predicted by a Protein Intrinsic Disorder Model Sheds Light on the COVID-19 (Wuhan-2019-nCoV) Infectivity. Biomolecules, 2020, vol. 10, no. 2, pp. E331. doi: 10.3390/biom10020331.
51. Goh K.J., Choong M.C., Cheong E.H., Kalimuddin S., Duu Wen S., Phua G.C., Chan K.S., Haja Mohideen S. Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection. Ann Acad Med Singapore, 2020, vol. 49, no. 3, pp. 1-9.
52. Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol, 2013, vol. 11, pp. 836-848. doi:10.1038/nrmicro3143.
53. Guan W.-J., Liang W.-H., Zhao Y., Liang H.-R., Chen Z.-S., Li Y.-M., Liu X.-Q., Chen R.-C., Tang C.-L., Wang T., Ou C.-Q., et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J, 2020, Mar 26. doi: 10.1183/13993003.00547-2020.
54. Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C., Qin R., Wang H., Shen Y., Du K., Zhao L., Fan H., Luo S., Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev, 2020, Mar 31, e3319. doi: 10.1002/dmrr.3319.
55. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 2020, vol. 7, no. 1, pp. 11. doi: 10.1186/s40779-020-00240-0.
56. Li H., Liu S.-M., Yu X.-H., Tang S.L., Tang C.K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents, 2020, Mar 29. doi: 10.1016/j.ijantimicag.2020.105951.
57. Habibzadeh P., Stoneman E.K. The Novel Coronavirus: A Bird’s Eye View. Int J Occup Environ Med, 2020, vol. 11, no. 2, pp. 65-71. doi: 10.15171/ijoem.2020.1921.
58. Hallow K.M., Greasley P.J., Helmlinger G., Chu L., Heerspink H.J., Boulton D.W. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Renal Physiol, 2018, vol. 315, no. 5, pp. F1295-F1306. doi:10.1152/ajprenal.00202.2018.
59. Han R., Huang L., Jiang H., Dong J., Peng H., Zhang D. Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. AJR Am J Roentgenol, 2020, vol. 17, pp. 1-6. doi: 10.2214/AJR.20.22961.
60. Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 2020, Apr 10, pii: /j/cclm. ahead-of-print/cclm-2020-0369/cclm-2020-0369.xml. doi: 10.1515/cclm-2020-0369.
61. Henry B.M., Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol, 2020. PMID: 32222883.
62. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, vol. 181, no. 2, pp. 271-280, pp. e8. doi: 10.1016/j.cell.2020.02.052.
63. Wenzhong L., Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism [electronic resource]. ChemPxiv. Available at: https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173
64. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 24, no. 20, pp. 30183–30185. doi: 10.1016/S0140-6736(20)30183-5.
65. Hung I.F., To K.K., Lee C.K., Chan K., Yan W.W., Liu R., Watt C.L., Chan W.M., Lai K.Y., Koo C.K., Buckley T., Chow F.L., Wong K.K., Chan H.S., Ching C.K., Tang B.S., Lau C.C., Li I.W., Liu S.H., Chan K.H., Lin C.K., Yuen K.Y. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis, 2011, vol. 52, no. 4, pp. 447-456. doi: 10.1093/cid/ciq106.
66. Iacobellis G. COVID-19 and Diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract, 2020, vol. 26, no. 162, pp. 108125. doi: 10.1016/j.diabres.2020.108125.
67. Jawhara S. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients? Int J Mol Sci, 2020, vol. 21, no. 7, pp. E2272. doi: 10.3390/ijms21072272.
68. Jiatong S., Lanqin L., Wenjun L. COVID-19 epidemic: disease characteristics in children. J Med Virol, 2020, Mar 31. doi: 10.1002/jmv.25807.
69. Jin Y.H., Cai L., Cheng Z.S., Cheng H., Deng T., Fan Y.P., Fang C., Huang D., Huang L.Q., Huang Q., Han Y., Hu B., Hu F., Li B.H., Li Y.R., Liang K., Lin L.K., Luo L.S., Ma J., Ma L.L., Peng Z.Y., Pan Y.B., Pan Z.Y., Ren X.Q., Sun H.M., Wang Y., Wang Y.Y., Weng H., Wei C.J., Wu D.F., Xia J., Xiong Y., Xu H.B., Yao X.M., Yuan Y.F., Ye T.S., Zhang X.C., Zhang Y.W., Zhang Y.G., Zhang H.M., Zhao Y., Zhao M.J., Zi H., Zeng X.T., Wang Y.Y., Wang X.H. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res, 2020, vol. 7, no. 1, pp. 4. doi: 10.1186/s40779-020-0233-6.
70. Johnson H.C., Gossner C.M., Colzani E., Kinsman J., Alexakis L., Beauté J., Würz A, Tsolova S., Bundle N., Ekdahl K. Potential scenarios for the progression of a COVID-19 epidemic in the European Union and the European Economic Area, March 2020. Euro Surveill, 2020, vol. 25, no. 9. doi: 10.2807/1560-7917.ES.2020.25.9.2000202.
71. Jones T. Coronavirus. Possible method for the production of a Covid-19 vaccine. Vet Record, 2020, 28 March, pp. 388.
72. Kalil A.C. Treating COVID-19 - off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020, March 24. doi:10.1001/jama.2020.4742.
73. Kannan S., Shaik Syed Ali P., Sheeza A., Hemalatha K. COVID-19 (Novel Coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci, 2020, vol. 24, no. 4, pp. 2006-2011. doi: 10.26355/eurrev_202002_20378.
74. Kay F., Abbara S. The Many Faces of COVID-19: Spectrum of Imaging Manifestations. Radiology: Cardiothoracic Imaging, 2020, vol. 2, no. 1, pp. e200037.
75. Ketai L., Paul N.S., Wong K.T. Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease. J Thorac Imaging, 2006, vol. 21, no. 4, pp. 276-283.
76. Khamitov R.A., Loginova S.I., Shchukina V.N., Borisevich S.V., Maksimov V.A., Shuster A.M. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol, 2008, vol. 53, no. 4, pp. 9-13. [in Russian]
77. Kinross P., Suetens C., Gomes Dias J., Alexakis L., Wijermans A., Colzani E., Monnet D.L.; European Centre For Disease Prevention And Control Ecdc Public Health Emergency Team2. Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020. Euro Surveill, 2020, vol. 25, no.11. doi: 10.2807/1560-7917.ES.2020.25.11.2000285.
78. Kooraki S., Hosseiny M., Myers L., Gholamrezanezhad A. Coronavirus (COVID-19) Outbreak: What the Department of Radiology Should Know. J Am Coll Radiol, 2020, vol. 17, no. 4, pp. 447-451. doi: 10.1016/j.jacr.2020.02.008.
79. Kotfis K., Skonieczna-Żydecka K. COVID-19: gastrointestinal symptoms and potential sources of 2019-nCoV transmission. Anaesthesiol Intensive Ther, 2020, Mar 23, pii: 40157. doi: 10.5114/ait.2020.93867.
80. Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B., Huan Y., Yang P., Zhang Y., Deng W., Bao L., Zhang B., Liu G., Wang Z., Chappell M., Liu Y., Zheng D., Leibbrandt A., Wada T., Slutsky A.S., Liu D., Qin C., Jiang C., Penninger J.M. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 2005, vol. 11, pp. 875-879. doi: 10.1038/nm1267 .
81. Kupferschmidt K., Cohen J. Race to find COVID-19 treatments accelerates. Science, 2020, vol. 367, no. 6485, pp. 1412-1413. doi: 10.1126/science.367.6485.1412.
82. Lai C.C., Liu Y.H., Wang C.Y., Wang Y.H., Hsueh S.C., Yen M.Y., Ko W.C., Hsueh P.R. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect, 2020, Mar 4. pii: S1684-1182(20)30040-2. doi: 10.1016/j.jmii.2020.02.012.
83. Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents, 2020, vol. 55, no. 3, pp. 105924. doi: 10.1016/j.ijantimicag.2020.105924.
84. Lake M.A. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond), 2020, vol. 20, no. 2, pp. 124-127. doi: 10.7861/clinmed.2019-coron.
85. Lee A. Wuhan novel coronavirus (COVID-19): why global control is challenging? Public Health, 2020, vol. 179, pp. A1-A2. doi: 10.1016/j.puhe.2020.02.001.
86. Leonsenso D., Pata D., Chiaretti A. COVID-19 outbreak: less stethoscope, more ultrasound. Lancet Respir Med, 2020, Mar 20, pii: S2213-2600(20)30120-X. doi: 10.1016/S2213-2600(20)30120-X.
87. Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov, 2020, vol. 19, no. 3, pp. 149-150. doi:10.1038/d41573-020-00016-0.
88. Li H., Liu S.M., Yu X.H., Tang S.L., Tang C.K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents, 2020, vol. 29, pp. 105951. doi: 10.1016/j.ijantimicag.2020.105951.
89. Li H., Zhou Y., Zhang M., Wang H., Zhao Q., Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother, 2020, Mar 23, pii: AAC.00483-20. doi: 10.1128/AAC.00483-20.
90. Li T., Lu H., Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect, 2020, vol. 9, no. 1, pp. 687-690. doi: 10.1080/22221751.2020.1741327.
91. Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol, 2020, Feb 27. doi: 10.1002/jmv.25728.
92. Lim J., Jeon S., Shin H.Y., Kim M.J., Seong Y.M., Lee W.J., Choe K.W., Kang Y.M., Lee B., Park S.J. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci, 2020, vol. 35, no. 6, pp. e79. doi: 10.3346/jkms.2020.35.e79.
93. Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect, 2020, vol. 9, no. 1, pp. 727-732. doi: 10.1080/22221751.2020.1746199.
94. Liu P.P., Blet A., Smyth D., Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation, 2020, Apr 15. doi: 10.1161/CIRCULATIONAHA.120.047549.
95. Liu Q., Wang R.S., Qu G.Q., Wang Y.Y., Liu P., Zhu Y.Z., Fei G., Ren L., Zhou Y.W., Liu L. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi, 2020, vol. 36, no. 1, pp. 21-23. doi: 10.12116/j.issn.1004-5619.2020.01.005.
96. Liu W., Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism [electronic resource]. ChemRxiv, 2020. Available at: https://doi.org/10.26434/chemrxiv.11938173.v7.
97. Liu W., Zhang Q., Chen J., Xiang R., Song H., Shu S., Chen L., Liang L., Zhou J., You L., Wu P., Zhang B., Lu Y., Xia L., Huang L., Yang Y., Liu F., Semple M.G., Cowling B.J., Lan K., Sun Z., Yu H., Liu Y. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med, 2020, vol. 382, no. 14, pp. 1370-1371. doi: 10.1056/NEJMc2003717.
98. Liu Y., Gayle A.A., Wilder-Smith A., Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med, 2020, vol. 27, no. 2, pp. taaa021. doi: 10.1093/jtm/taaa021.
99. Loeffelholz M.J., Tang Y.W. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect, 2020, vol. 9, no. 1, pp. 747-756. doi: 10.1080/22221751.2020.1745095.
100. Lu G., Wang Q., Gao G.F. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol, 2015, vol. 23, no. 8, pp. 468-478. doi: 10.1016/j.tim.2015.06.003.
101. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends, 2020, vol. 14, no. 1, pp. 69-71. doi: 10.5582/bst.2020.01020.
102. Ludvigsson J.F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr, 2020, Mar 23. doi: 10.1111/apa.15270.
103. Ma W.X., Ran X.W. The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19. Sichuan Da Xue Xue Bao Yi Xue Ban, 2020, vol. 51, no. 2, pp. 146-150. doi: 10.12182/20200360606.
104. Ma Y., Diao B., Lv X. et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan, China. Blog – NephJC, 2020. doi:10.1101/2020.02.24.20027201.
105. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K., et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015, vol. 211, no. 1, pp. 80-90. doi: 10.1093/infdis/jiu396.
106. Makhnevich A., Sinvani L., Cohen S.L., et al. The Clinical Utility of Chest Radiography for Identifying Pneumonia: Accounting for Diagnostic Uncertainty in Radiology Reports. Am. J Roentgenol, 2019, vol. 213, no. 6, pp. 1207-1212.
107. Marchand-Senécal X., Kozak R., Mubareka S., Salt N., Gubbay J.B., Eshaghi A., Allen V., Li Y., Bastien N., Gilmour M., Ozaldin O., Leis J.A. Diagnosis and Management of First Case of COVID-19 in Canada: Lessons applied from SARS. Clin Infect Dis, 2020, Mar 9, pii: ciaa227. doi: 10.1093/cid/ciaa227.
108. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020, vol. 395, no. 10229, pp. 1033-1034. doi:10.1016/S0140-6736(20)30628-0.
109. Memish Z.A., Al-Tawfiq J.A., Assiri A. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J, 2014, vol. 33, pp. 904.
110. Morlton CL, Babady E, Ginocchio CC, et al. Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections. Clin Microbiol Rev, 2019, vol. 32, pp. 28-42.
111. Moorthy V., Henao Restrepo A.M., Preziosi M.P., Swaminathan S. Data sharing for novel coronavirus (COVID-19). Bull World Health Organ, 2020, vol. 98, no. 3, pp. 150. doi: 10.2471/BLT.20.251561.
112. Nair A., Rodrigues J.C.L., Hare S., Edey A., Devaraj A., Jacob J., Johnstone A., McStay R., Denton E., Robinson G. A British Society of Thoracic Imaging statement: considerations in designing local imaging diagnostic algorithms for the COVID-19 pandemic. Clin Radiol, 2020, vol. 75, no. 5, pp. 329-334. doi: 10.1016/j.crad.2020.03.008.
113. Nakajima K., Kato H., Yamashiro T., Izumi T., Takeuchi I., Nakajima H., Utsunomiya D. COVID-19 pneumonia: infection control protocol inside computed tomography suites. Jpn J Radiol, 2020, Mar 17. doi: 10.1007/s11604-020-00948-y.
114. National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7) [electronic resource]. Available at: https://www.chinalawtranslate.com/wp-content/uploads/2020/03/Who-translation.pdf. (accessed 18.03. 2020).
115. Ng M.Y., Lee E.Y.P., Yang J, et al. Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review. Radiology: Cardiothoracic Imaging. 2020, 2020, vol. 2, no. 1, pp. e200034.
116. Nguyen T., Duong Bang D., Wolff A. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics. Micromachines (Basel), 2020, vol. 11, no. 3, pp. E306. doi: 10.3390/mi11030306.
117. Palacios Cruz M., Santos E., Velázquez Cervantes M.A., León Juárez M. COVID-19, a worldwide public health emergency. Rev Clin Esp, 2020, Mar 20, pp. S0014-2565(20)30092-8. doi: 10.1016/j.rce.2020.03.001.
118. Pan F., Ye T., Sun P., Gui S., Liang B., Li L., Zheng D., Wang J., Hesketh R.L., Yang L., Zheng C. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology, 2020, Feb 13. doi: 10.1148/radiol.2020200370.
119. Panahi L., Amiri M., Pouy S. Risks of Novel Coronavirus Disease (COVID-19) in Pregnancy; a Narrative Review. Arch Acad Emerg Med, 2020, vol. 8, no. 1, pp. e34.
120. Patel R., Babady E., Theel E.S., Storch G.A., Pinsky B.A., St George K., Smith T.C., Bertuzzi S. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS-CoV-2/COVID-19. mBio, 2020, vol. 11, no. 2, pp. e00722-20. doi: 10.1128/mBio.00722-20.
121. Puig-Domingo M., Marazuela M., Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine, 2020, Apr 11. doi: 10.1007/s12020-020-02294-5.
122. Pung R., Chiew C.J., Young B.E., Chin S., Chen M.I., Clapham H.E., Cook A.R., Maurer-Stroh S., Toh M.P.H.S., Poh C., Low M., Lum J., Koh V.T.J., Mak T.M., Cui L., Lin R.V.T.P., Heng D., Leo Y.S., Lye D.C., Lee V.J.M. ; Singapore 2019 Novel Coronavirus Outbreak Research Team. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet, 2020, vol. 395, no. 10229, pp. 1039-1046. doi: 10.1016/S0140-6736(20)30528-6.
123. Qin C., Liu F., Yen T.C., Lan X. 18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. Eur J Nucl Med Mol Imaging, 2020, vol. 47, no. 5, pp.1281-1286. doi: 10.1007/s00259-020-04734-w.
124. Rao T.N., Paul N., Chung T., Mazzulli T., Walmsley S., Boylan C.E., Provost Y., Herman S.J., Weisbrod G.L., Roberts H.C. Value of CT in Assessing Probable Severe Acute Respiratory Syndrome. AJR Am J Roentgenol, 2003, vol. 181, no. 2, pp. 317-319.
125. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol, 2020, Mar 26. doi: 10.1111/jdv.16387.
126. Robson B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Comput Biol Med, 2020, vol. 119, pp. 103670. doi: 10.1016/j.compbiomed.2020.103670.
127. Rossi S.E., Erasmus J.J., Volpacchio M., Franquet T., Castiglioni T., McAdams H.P. «Crazy-Paving» Pattern at Thin-Section CT of the Lungs: Pathologic Overview. RadioGraphics, 2003, vol. 23, no. 6, pp. 1509-1519.
128. Ruan, Q., Yang, K., Wang, W., et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med, 2020. doi: 10.1007/s00134-020-05991.
129. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, vol. 395, no. 10223, pp. 473-475. doi: 10.1016/S0140-6736(20)30317-2.
130. Ryu S., Chun B.C.; Korean Society of Epidemiology 2019-nCoV Task Force Team1. An interim review of the epidemiological characteristics of 2019 novel coronavirus. Epidemiol Health, 2020, vol. 42, pp. e2020006. doi: 10.4178/epih.e2020006.
131. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 2020, April 13. doi:10.1001/jama.2020.6019.
132. Shahid Z., Kalayanamitra R., McClafferty B., Kepko D., Ramgobin D., Patel R., Aggarwal C.S., Vunnam R.R., Sahu N., Bhatt D., Jones K., Golamari R., Jain R. J. COVID-19 And Older Adults: What We Know. Am Geriatr Soc, 2020, Apr 7. doi: 10.1111/jgs.16472.
133. Shang L., Zhao J., Hu Y., Du R., Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet, 2020, vol. 395, no. 10225, pp. 683-684. doi: 10.1016/S0140-6736(20)30361-5.
134. Shanmugaraj B., Siriwattananon K., Wangkanont K., Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol, 2020, vol. 38, no. 1, pp. 10-18. doi: 10.12932/AP-200220-0773.
135. Sheahan T.P., Sims A.C., Leist S.R., Schafer A., Won J., Brown A.J., Brown A.J., Montgomery S.A., Hogg A., Babusis D., Clarke M.O., Spahn J.E., Bauer L., Sellers S., Porter D., Feng J.Y., Cihlar T., Jordan R., Denison M.R., Baric R.S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 2020, vol. 11, no. 1, pp. 222. doi: 10.1038/s41467-019-13940-6.
136. Shereen M.A., Khan S., Kazmi A., Bashir N., Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res, 2020, vol. 16, no. 24, pp. 91-98. doi: 10.1016/j.jare.2020.03.005.
137. Shi H., Han X., Jiang N., Cao Y., Alwalid O., Gu J., Fan Y., Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 2020, vol. 20, no. 4, pp. 425-434. doi: 10.1016/S1473-3099(20)30086-4.
138. Shi Y., Yu X., Zhao H., Wang H., Zhao R., Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care, 2020, vol. 24, no. 1, pp. 108. doi: 10.1186/s13054-020-2833-7.
139. Siddiqu H.K., Mehra M.R. COVID-19 Illness in Native and Immunosuppressed States: A Clinical- Therapeutic Staging Proposal. J Heart Lung Transplantation, 2020, 25 Mar 25. doi: 10.1016/j.healun.2020.03.012.
140. Sifuentes-Rodríguez E., Palacios-Reyes D. COVID-19: The outbreak caused by a new coronavirus. Bol Med Hosp Infant Mex, 2020, vol. 77, no. 2, pp. 47-53. doi: 10.24875/BMHIM.20000039.
141. Singh A.K., Gupta R., Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr, 2020, vol. 14, no. 4, pp. 283-287. doi: 10.1016/j.dsx.2020.03.016.
142. Singhal T.A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr, 2020, vol. 87, no. 4, pp. 281-286. doi: 10.1007/s12098-020-03263-6.
143. Sohrabi C., Alsafi Z., O’Neill N., Khan M., Kerwan A., Al-Jabir A., Iosifidis C., Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg, 2020, Apr 76, pp. 71-76. doi: 10.1016/j.ijsu.2020.02.034.
144. Song F., Shi N., Shan F., Zhang Z., Shen J., Lu H., Ling Y., Jiang Y., Shi Y. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology, 2020, vol. 295, no. 1, pp. 210-217. doi: 10.1148/radiol.2020200274.
145. Song P., Karako T. COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends, 2020, vol. 14, no. 1, pp. 1-2. doi: 10.5582/bst.2020.01056.
146. Spagnuolo G., De Vito D., Rengo S., Tatullo M. COVID-19 Outbreak: An Overview on Dentistry. Int J Environ Res Public Health, 2020, vol. 17, no. 6, pp. E2094. doi: 10.3390/ijerph17062094.
147. Stockman L.J., Bellamy R., Garner P. SARS: systematic review of treatment effects. PLoS Med, 2006, vol. 3, no. 9, pp. e343. doi: 10.1371/journal.pmed.0030343.
148. Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. Liver Int, 2020, Apr 6. doi: 10.1111/liv.14470.
149. Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. J Med Virol, 2020, Feb 25. doi: 10.1002/jmv.25722.
150. Tan C., Huang Y., Shi F., Tan K., Ma Q., Chen Y., Jiang X., Li X. C-reactive protein correlates with CT findings and predicts severe COVID-19 early. J Med Virol, 2020, Apr 13. doi: 10.1002/jmv.25871.
151. Tan W., Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol, 2020, Mar 28, S0167-5273(20)31593-X. doi: 10.1016/j.ijcard.2020.03.063.
152. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020, vol. 18, no. 4, pp. 844-847. doi: 10.1111/jth.14768.
153. Tapé C., Byrd K.M., Aung S., Lonks J.R., Flanigan T.P., Rybak N.R. COVID-19 in a Patient Presenting with Syncope and a Normal Chest X-ray. R I Med J, 2020, vol. 103, no. 3, pp. 50-51.
154. Tchesnokov E.P., Feng J.Y., Porter D.P., Gotte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA Polymerase by remdesivir. Viruses, 2019, vol. 11, no. 4, pp. E326. doi: 10.3390/v11040326.
155. Terpos E., Ntanasis-Stathopoulos I., Elalamy I., Kastritis E., Sergentanis T.N., Politou M., Psaltopoulou T., Gerotziafas G., Dimopoulos M.A. Hematological findings and complications of COVID-19. Am J Hematol, 2020, Apr 13. doi: 10.1002/ajh.25829.
156. Tetro J.A.. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect, 2020, vol. 22, no. 2, pp. 72-73. doi: 10.1016/j.micinf.2020.02.006.
157. Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M., Clark C., Iba T. IISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemostasis, 2020, Mar 25. doi: 10.1111/jth.14810.
158. Tian S., Hu N., Lou J., Chen K., Kang X., Xiang Z., Chen H., Wang D., Liu N., Liu D., Chen G., Zhang Y., Li D., Li J., Lian H., Niu S., Zhang L., Zhang J. Characteristics of COVID-19 infection in Beijing. J Infect, 2020, vol. 80, no. 4, pp. 401-406. doi: 10.1016/j.jinf.2020.02.018.
159. Tian S., Hu W., Niu L., Liu H., Xu H., Xiao S.-Y. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol, 2020,, Feb 28. doi: 10.1016/j.jtho.2020.02.010.
160. Tisdale J.E. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott), 2016, vol. 149, no. 3, pp. 139-152. doi: 10.1177/1715163516641136.
161. To K.K., Tsang O.T., Chik-Yan Y.C., Chan K.H. Wu T.C., Chan J.M.C., Leung W.S., Chik T.S., Choi C.Y., Kandamby D.H., Lung D.C., Tam A.R., Poon R.W., Fung A.Y., Hung I.F., Cheng V.C., Chan J.F., Yuen K.Y. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis, 2020. Feb 12. pii: ciaa149. doi: 10.1093/cid/ciaa149.
162. Tolksdorf K., Buda S., Schuler E., Wieler L.H., Haas W. Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19). Euro Surveill, 2020, vol. 25, no. 11. doi: 10.2807/1560-7917.ES.2020.25.11.2000258.
163. Totura A.L., Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov, 2019, vol. 14, no. 4, pp. 397-412. doi: 10.1080/17460441.2019.1581171.
164. Touret F., de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res, 2020, vol. 5, no. 177, pp. 104762. doi: 10.1016/j.antiviral.2020.104762.
165. Tveito K. Cytokine storms in COVID-19 cases? Tidsskr Nor Laegeforen, 2020, vol. 23, pp. 140. doi: 10.4045/tidsskr.20.0239.
166. Vankadari N., Wilce J.A. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect, 2020, vol. 9, no. 1, pp. 601-604. doi: 10.1080/22221751.2020.1739565.
167. Velavan T.P., Meyer C.G. The COVID-19 epidemic. Trop Med Int Health, 2020, vol. 25, no. 3, pp. 278-280. doi: 10.1111/tmi.13383.
168. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, vol. 30, no. 3, pp. 269-271. doi: 10.1038/s41422-020-0282-0.
169. Wang H., Wang S., Yu K. COVID-19 infection epidemic: the medical management strategies in Heilongjiang Province, China. Crit Care, 2020, vol. 24, no. 1, pp. 107. doi: 10.1186/s13054-020-2832-8.
170. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, vol. 30, no. 3, pp. 269-271. doi: 10.1038/s41422-020-0282-0.
171. Wang W, Xu Y, Gao R, Lu R., Han K., Wu G., Tan W. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA, 2020, Mar 11. doi: 10.1001/jama.2020.3786.
172. Wang W., Lu J., Gu W., Zhang Y., Liu J., Ning G. Care for diabetes with COVID-19: Advice from China. J Diabetes, 2020, Apr 13. doi: 10.1111/1753-0407.13036.
173. Wang Y.Y., Jin Y.H., Ren X.Q., Li Y.R., Zhang X.C., Zeng X.T., Wang X.H. ; Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team. Updating the diagnostic criteria of COVID-19 “suspected case” and “confirmed case” is necessary. Mil Med Res, 2020, vol. 7, no. 1, pp. 17. doi: 10.1186/s40779-020-00245-9.
174. Wei J., Xu H., Xiong J., Shen Q., Fan B., Ye C., Dong W., Hu F. 2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings. Korean J Radiol, 2020, vol. 21, no. 4, pp. 501-504. doi: 10.3348/kjr.2020.0112.
175. Weston S., Frieman M.B. COVID-19: Knowns, Unknowns, and Questions. mSphere, 2020, vol. 5, no. 2, pp. e00203-20. doi: 10.1128/mSphere.00203-20.
176. Wilder-Smith A., Freedman D.O. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med, 2020, vol. 27, no. 2, pp. taaa020. doi: 10.1093/jtm/taaa020.
177. World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected [electronic resource]. Updated March 13, 2020. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. (accessed 18.03.2020).
178. Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, vol. 367, no. 6483, pp. 1260-1263. doi: 10.1126/science.abb2507.
179. Wu C.I., Postema P.G., Arbelo E., Behr E.R., Bezzina C.R., Napolitano C., Robyns T., Probst V., Schulze-Bahr E., Remme C.A., Wilde A.A.M. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm, 2020, Mar 31:S1547-5271(20)30285-X. doi: 10.1016/j.hrthm.2020.03.024.
180. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Zhang Y., Song J., Wang S., Chao Y., Yang Z., Xu J., Zhou X., Chen D., Xiong W., Xu L., Zhou F., Jiang J., Bai C., Zheng J., Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 2020, Mar 13. doi: 10.1001/jamainternmed.2020.0994.
181. Wu D., Wu T., Liu Q., Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis, 2020, Mar 11, pii: S1201-9712(20)30123-5. doi: 10.1016/j.ijid.2020.03.004.
182. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., Yuan M.L., Zhang Y.L., Dai F.H., Liu Y., Wang Q.M., Zheng J.J., Xu L., Holmes E.C., Zhang Y.Z. A new coronavirus associated with human respiratory disease in China. Nature, 2020, vol. 579, no. 7798, pp. 265-269. doi: 10.1038/s41586-020-2008-3.
183. Wu Y., Xie Y., Wang X. Longitudinal C.T. Findings in COVID-19 Pneumonia: Case Presenting Organizing Pneumonia Pattern. Radiology: Cardiothoracic Imaging. 2020, 2020, vol. 2, no. 1, pp. e200031.
184. Wu Y.C., Chen C.S., Chan Y.J. The outbreak of COVID-19: An overview. J Chin Med Assoc, 2020, vol. 83, no. 3, pp. 217-220. doi: 10.1097/JCMA.0000000000000270.
185. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease Control and prevention. J Am Med Assoc, 2020, Feb 24.
186. Xiao Y., Tan C., Duan J., Wu A., Li C. An Effective Model for the Outpatient Management of COVID-19. Infect Control Hosp Epidemiol, 2020, vol. 26, pp. 1-4. doi: 10.1017/ice.2020.92.
187. Xie Y., Wang X., Yang P., Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiology: Cardiothoracic Imaging. 2020, 2020, vol. 2, no. 2, pp. e200067. doi: 10.1148/ryct.2020200067.
188. Xiong Y., Liu Y., Cao L., Wang D., Guo M., Jiang A., Guo D., Hu W., Yang J., Tang Z., Wu H., Lin Y., Zhang M., Zhang Q., Shi M., Liu Y., Zhou Y., Lan K., Chen Y. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect, 2020, vol. 9, no. 1, pp. 761-770. doi: 10.1080/22221751.2020.1747363.
189. Xiong Y., Sun D., Liu Y., Fan Y., Zhao L., Li X., Zhu W. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes. Invest Radiol, 2020, Mar 3. doi: 10.1097/RLI.0000000000000674.
190. Xu B., Gutierrez B., Mekaru S., Sewalk K., Goodwin L., Loskill A., Cohn E.L., Hswen Y., Hill S.C., Cobo M.M., Zarebski A.E., Li S., Wu C.H., Hulland E., Morgan J.D., Wang L., O’Brien K., Scarpino S.V., Brownstein J.S., Pybus O.G., Pigott D.M., Kraemer M.U.G. Epidemiological data from the COVID-19 outbreak, real-time case information. Sci Data, 2020, vol. 7, no. 1, pp. 106. doi: 10.1038/s41597-020-0448-0.
191. Xu X., Yu C., Qu J., Zhang L., Jiang S., Huang D., Chen B., Zhang Z., Guan W., Ling Z., Jiang R., Hu T., Ding Y., Lin L., Gan Q., Luo L., Tang X., Liu J. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging, 2020, vol. 47, no. 5, pp. 1275-1280. doi: 10.1007/s00259-020-04735-9.
192. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, Feb 18. doi: 10.1016/S2213-260 0(20)30 076-X.
193. Yang D., Leibowitz J.L. The structure and functions of coronavirus genomic 3 and 5 ends. Virus Res, 2015, vol. 206, pp. 120-133. doi: 10.1016/j.virusres. 2015.02.025.
194. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis, 2020 Mar 12. doi: 10.1016/j.ijid.2020.03.017.
195. Yang T., Wang Y.C., Shen C.F., Cheng C.M. Point-of-Care RNA-Based Diagnostic Device for COVID-19. Diagnostics (Basel), 2020, vol. 10, no. 3, pp. E165. doi: 10.3390/diagnostics10030165.
196. Yao T.T., Qian J.D., Zhu W.Y., Wang Y., Wang G.Q. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol, 2020, Feb 27. doi:10.1002/jmv.25729.
197. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P., Liu X., Zhao L., Dong E., Song C., Zhan S., Lu R., Li H., Tan W., Liu D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 2020, Mar 9. doi: 10.1093/cid/ciaa237.
198. Yao R.-Q., Ren C., Wu G.-S., Zhu Y.-B., Xia Z.-F., Yao Y.-M. Is intensive glucose control bad for critically ill patients? A systematic review and meta-analysis. Int J Biol Sci, 2020, vol. 16, no. 9, pp. 1658-1675. doi: 10.7150/ijbs.43447.
199. Yin S., Huang M., Li D., Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis, 2020, Apr 3, pp. 1-4. doi: 10.1007/s11239-020-02105-8.
200. Young B.E., Ong S.W.X, Kalimuddin S., Low J.G., Tan S.Y., Loh J., Ng O.T., Marimuthu K., Ang L.W., Mak T.M., Lau S.K., Anderson D.E. Chan K.S., Tan T.Y., et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA, 2020, Mar 3. doi: 10.1001/jama.2020.3204.
201. Yuen K.S., Ye Z.W., Fung S.Y., Chan C.P., Jin D.Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci, 2020, vol. 16, no. 10, pp. 40. doi: 10.1186/s13578-020-00404-4.
202. Zhang P., Zhu L., Cai J., Lei F., Qin J., Xie J., Liu Y-M, Zhao Y-C, Huang X., Lin L., Xia M., Chen M-M, Cheng X., Zhang X., Guo D., Peng Y., Ji Y-X., Chen J., She Z-G., Wang Y.; Xu Q., Tan R., Wang H., Lin J., Luo P., Fu S., Cai H., Ye P., Xiao B., Mao W., Liu L., Yan Y., Liu M., Chen M., Zhang X-J., Wang X., Touyz R. M., Xia J., Zhang B-H., Huang X., Yuan Y., Loomba R., Liu P. P., Li H. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res, 2020, Apr 17. doi: 10.1161/CIRCRESAHA.120.317134.
203. Zhang W., Du R.H., Li B., Zheng X.S., Yang X.L., Hu B., Wang Y.Y., Xiao G.F., Yan B., Shi Z.L., Zhou P. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect, 2020, vol. 9, no. 1, pp. 386-389. doi: 10.1080/22221751.2020.1729071.
204. Zhao Q., Meng M., Kumar R., Wu Y., Huang J., Lian N., Deng Y., Lin S. The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis. J Med Virol, 2020, Apr 15. doi: 10.1002/jmv.25889.
205. Zhong B.L., Luo W., Li H.M., Zhang Q.Q., Liu X.G., Li W.T., Li Y. Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey. Int J Biol Sci, 2020, vol. 16, no. 10, pp. 1745-1752. doi: 10.7150/ijbs.45221.
206. Zhou D., Dai S.M., Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother, 2020, Mar 20. doi: 10.1093/jac/dkaa114.
207. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, vol. 395, no. 10229, pp. 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
208. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J. Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, vol. 579, no. 7798, pp. 270-273. doi: 10.1038/s41586-020-2012-7.
209. Zhu J., Ji P., Pang J., Zhong Z., Li H., He C., Zhang J., Zhao C. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol, 2020, Apr 15. doi: 10.1002/jmv.25884.
210. Zu Z.Y., Jiang M.D., Xu P.P., Chen W., Ni Q.Q., Lu G.M., Zhang L.J. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology, 2020, Feb 21, pp. 200490. doi: 10.1148/radiol.2020200490.
211. Zumla A., Hui D.S., Perlman S. Middle East respiratory syndrome. Lancet, 2015, vol. 386, no. 9997, pp. 995-1007. doi: 10.1016/S0140-6736(15)60454-8.
File extension: pdf (2.27 MB)